Text Size

The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

This study is currently recruiting participants.
Verified September 2007 by Showa Inan General Hospital
Sponsor:
Information provided by (Responsible Party):
Akira Horiuchi, Showa Inan General Hospital
ClinicalTrials.gov Identifier:
NCT00596401
First received: January 8, 2008
Last updated: August 21, 2011
Last verified: September 2007
History of Changes
  Purpose

Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.


Condition
Helicobacter Pylori
Eradication
Gastric Cancer
Medical Care Cost

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Showa Inan General Hospital:

Primary Outcome Measures:
  • the annual incidence of gastric cancer in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The annual medical care cost in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

serum


Estimated Enrollment: 3000
Study Start Date: September 2007
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
HP eradication group
2
No eradication group
3
No Hp group

  Eligibility

Ages Eligible for Study:   19 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

People who live in Iijima town

Criteria

Inclusion Criteria:

  • People who live in Iijima town at their age of 19 to 69 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596401

Contacts
Contact: Akira Horiuchi, M.D. 81265822121 ext 3012 horiuchi.akira@sihp.jp

Locations
Japan
Showa Inan General hospital Recruiting
Komagane, Nagano, Japan, 399-4191
Contact: Akira Horiuchi, M.D.     81265822121 ext 3012     horiuchi.akira@sihp.jp    
Principal Investigator: Akira Horiuchi, M.D.            
Sponsors and Collaborators
Showa Inan General Hospital
Investigators
Study Director: Akira Horiuchi, M.D. Showa Inan General Hospital
  More Information

No publications provided

Responsible Party: Akira Horiuchi, Digestive Disease Center, Showa Inan General Hospital
ClinicalTrials.gov Identifier: NCT00596401     History of Changes
Other Study ID Numbers: sihp20076
Study First Received: January 8, 2008
Last Updated: August 21, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases

ClinicalTrials.gov processed this record on May 19, 2013